Golden Nuggets - Closing Remarks

•Download as PPT, PDF•

0 likes•334 views

jehill3

Golden Nuggets - Closing Remarks Tom Davis, Chairman of the Board, CORE Group CORE Group Spring Meeting, April 30, 2010

Health & Medicine

Questions ,[object Object],[object Object],[object Object],[object Object]

Recently uploaded

The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...

Catherine Liao

Young at heart: Cardiovascular health stations to empower healthy lifestyle b...

Catherine Liao

Effects of vaping e-cigarettes on arterial health

Catherine Liao

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

Ocular injury ppt Upendra pal optometrist upums saifai etawah

pal078100

CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx

Dr KHALID B.M

ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx

Bright Chipili

Evaluation of antidepressant activity of clitoris ternatea in animals

Shweta

Presentació "Advancing Emergency Medicine Education through Virtual Reality"

Badalona Serveis Assistencials

Scientificity and feasibility study of non-invasive central arterial pressure...

Catherine Liao

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Catherine Liao

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Catherine Liao

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

Contact us if you are interested: Email / Skype : kefaya1771@gmail.com Threema: PXHY5PDH New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH ! Contact me on Threema or skype to start big business!! Hot-sale products: NEW HOT EUTYLONE WHITE CRYSTAL!! 5cl-adba precursor (semi finished ) 5cl-adba raw materials ADBB precursor (semi finished ) ADBB raw materials APVP powder 5fadb/4f-adb Jwh018 / Jwh210 Eutylone crystal Protonitazene (hydrochloride) CAS: 119276-01-6 Flubrotizolam CAS: 57801-95-3 Metonitazene CAS: 14680-51-4 Payment terms: Western Union,MoneyGram,Bitcoin or USDT. Deliver Time: Usually 7-15days Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet. Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details. We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

GL Anaacs

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

drwaque

TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...

kevinkariuki227

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

Savita Shen $i11

Compare home pulse pressure components collected directly from home

Catherine Liao

Gauri Gawande(9) Constipation Final.pptx

gauripg8

Recently uploaded (20)